Press Release

Mitsubishi Tanabe Pharma Corporation

Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria

Osaka, Japan, April 3, 2013—Mitsubishi Tanabe Pharma Corporation (President and Representative Director, CEO: Michihiro Tsuchiya) announced today that its consolidated subsidiary, Mitsubishi Pharma Deutschland GmbH (hereafter, MPD; headquartered in Dusseldorf, Germany) began marketing non-absorbed phosphate binder, BindRen®* (generic name: colestilan) in Germany and Austria.

In patients with impaired renal function, phosphorus is not sufficiently excreted into the urine via the kidneys and accumulates in the body, which can lead to hyperphosphatemia. Persistent hyperphosphatemia causes secondary hyperparathyroidism and even nephrogenic osteopathy characterized by bone pain and a tendency for bone fracture. Additionally, phosphorus binds to calcium to form calcium phosphate, which in turn causes calcinosis on vascular walls, heart, lungs and other internal organs, as well as periarticular areas; and this represents an increased risk for cardiovascular disease.

BindRen® is a non-absorbed anion exchange resin for oral administration. In the clinical studies it improved high blood phosphorus concentration by adsorbing phosphoric acid in the gastrointestinal tract and excrete it into the feces. Also observed are LDL cholesterol and HbA1c level reductions thanks to bile acid adsorption in the gastrointestinal tract, as well as serum uric acid level reduction. Reported common adverse reactions include nausea, vomiting, and indigestion.

Mitsubishi Pharma Europe Ltd., its consolidated subsidiary, (hereafter, MPE; headquartered in London, UK), developed BindRen® for the treatment of hyperphosphataemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis in Europe, and received the marketing authorization in January 2013, and has been preparing for marketing in Germany and Austria by MPD. MPE is considering to market BindRen® in UK and other countries in Europe.

Mitsubishi Tanabe Pharma positioned BindRen® as an important product of the kidney disease field in European business, and expects to establish a foundation for the marketing in Germany and other European countries and contribute to improving quality of life for patients with chronic kidney disease through this introduction of BindRen®.

*: The product has been marketed since 1999 in Japan, for the treatment of hypercholesterolemia under the brand name of CHOLEBINE®

<<Contact for Inquiries>>
Corporate Communications Department
Phone: +81-6-6205-5211